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Abstract 
A state-wide pertussis outbreak occurred in Washington during the winter–spring months of 2012, concurrent with 
respiratory viral season. We compared performance characteristics of a laboratory-developed pertussis PCR (LD-PCR 
for Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii) and rapid multiplex PCR (RM-PCR) for respira-
tory viruses (FilmArray™, BioFire, B. pertussis data unblinded following FDA approval post outbreak). We analyzed three 
cohorts of patients using physician testing orders as a proxy for clinical suspicion for pertussis or respiratory viruses: 
Cohort 1, tested by LD-PCR for pertussis pathogens only by nasopharyngeal swab; Cohort 2, by RM-PCR for respira-
tory viruses only by mid-nasal turbinate swab; and Cohort 3, by both methods. B. pertussis was detected in a total 
of 25 of the 490 patients in Cohort 3 in which LD-PCR detected 20/25 (80 %) cases and the RM-PCR detected 24/25 
(96 %; p = 0.2). Pertussis pathogens were detected in 21/584 (3.6 %) of samples from Cohort 1 where clinicians had 
a relatively strong suspicion for pertussis. In contrast, B. pertussis was detected in only 4/3071 (0.1 %) specimens from 
Cohort 2 where suspicion for pertussis was lower (p < 0.001 for comparison with Cohort 1). In summary, the two labo-
ratory methods were comparable for the detection of B. pertussis.
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Background
Resurgence of pertussis disease has been documented 
in the United States [1]. Nearly 5000 Bordetella pertus-
sis cases were reported in Washington State in 2012, the 
highest in 70  years [2, 3]. During respiratory seasons, 
clinical differentiation of pertussis from viral pathogens is 
problematic in pediatric populations, especially in young 
children [4, 5]. Identification of pertussis pathogens—as 
well as other agents causing respiratory and cough ill-
nesses—has important implications for patient care, vac-
cination recommendations, antimicrobial stewardship, 
and implementation of appropriate hospital—and com-
munity-based infection prevention.
Historically, laboratory diagnosis of pertussis and res-
piratory viral pathogens required technically demand-
ing methods maintained by specialized laboratories. 
Polymerase-chain-reaction (PCR) has greatly improved 
test sensitivity and reduced the time-to-result, enabling 
pathogen detection in patients long after symptom onset 
or antibiotic therapy [6]. However, most PCR tests pro-
vide high throughput capacity but not rapid real-time test 
results due to the common practice of batching samples 
to gain efficiency [7, 8]. Moreover, laboratory diagnosis 
of respiratory infections has been affected by substan-
tial variations in collection and transport methods. The 
emergence of US Food and Drug Administration (FDA)-
approved automated, rapid “mega”-multiplex PCR plat-
forms (RM-PCR) such FilmArray™ (BioFire, Salt Lake 
City, UT) exemplifies a technical breakthrough, enabling 
rapid diagnosis of acute viral and bacterial respiratory 
infections from a swab specimen and a single molecular 
panel.
The well-recognized 2012 pertussis outbreak in Wash-
ington State overlapped a respiratory viral season char-
acterized by wide-spread circulation of influenza, 
respiratory syncytial virus (RSV), and other respiratory 
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viruses (Fig.  1) [7, 9]. Both RM-PCR (FilmArray) for 
respiratory viruses and a laboratory-developed PCR 
(LD-PCR) for three pertussis pathogens (B. pertussis, 
B. parapertussis, and B. holmesii) were deployed dur-
ing this outbreak [8]. At the time, detection of B. pertus-
sis was included within the panel of RM-PCR panel but 
results were unavailable to laboratory for reporting pend-
ing FDA approval. B. pertussis detection results were 
obtained post hoc following licensure of the expanded 
RM-PCR panel by FDA in October 2012 [10]. In addition 
to increased laboratory utilization of high throughput 
LD-PCR during the pertussis outbreak, our diagnostic 
operation also included culture for all PCR-positive sam-
ples, achieving a 48 % culture-positivity rate that was use-
ful in statewide epidemiological studies of pertussis [3].
In this report, we compare results from our in-house 
LD-PCR—which enabled batching and high through-
put—with those from the rapid multiplex RM-PCR assay. 
We defined the performance characteristics of these two 
different approaches in identifying pertussis pathogens 
and analyzed the utility of RM-PCR during the overlap-
ping viral respiratory season in the pediatric urgent care 
and hospital-based setting.
Methods
Overview and specimen inclusion criteria
The protocol for this retrospective cohort study was 
approved by Seattle Children’s Institutional Review 
Board. All authors declare no competing interests that 
could potentially influence data analysis and conclusions.
We analyzed specimens collected from patients aged 
from birth to 21 years at Seattle Children’s Hospital from 
December 14, 2011 (the date of RM-PCR implementa-
tion replacing all other methods for respiratory viral 
diagnosis prior to the pertussis outbreak) to July 31, 2012 
(the month after the end of the 2012 respiratory viral sea-
son). The respiratory viral season was defined post hoc as 
the period of time encompassing peak volume of submit-
ted respiratory specimens. All specimens from patients 
obtained during inpatient and ambulatory visits, includ-
ing Emergency Department (ED) and Urgent Care facili-
ties, were eligible for inclusion. However, during this time 
period, the FDA cleared RM-PCR was restricted to test-
ing and reporting of respiratory viruses while LD-PCR is 
specifically used for the pertussis diagnosis. Post hoc data 
recovery pertaining to B. pertussis detection by RM-PCR 
was made available through the manufacture upon FDA 
clearance of the expanded panel in October 2012.
Samples were excluded from analysis if patients had 
underlying severe immunosuppressive conditions (hema-
tological or oncologic malignancies, or hematopoietic 
stem cell transplantation), or were in intensive care units 
(unless they were tested first in the ED) due to frequent 
repeat testing and active surveillance protocols associ-
ated with these patients. Inclusion and exclusion crite-
ria for repeat patient specimens were as follows: (1) for 
Fig. 1 Number of laboratory reported pertussis and respiratory viral infections during the 7.5 month study period (December 14, 2011–July 31, 
2012)
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pertussis LD-PCR diagnosis, repeat specimens from the 
same patient within 4 weeks with identical results (both 
positive, both negative) were excluded; (2) for respiratory 
viral diagnosis by RM-PCR, repeat specimen(s) result-
ing in detection of the same agent(s) in ≤14-day period 
were excluded; (3) detection of different viruses on repeat 
specimens from a single patient >14 days apart were con-
sidered to reflect different infectious episodes, and each 
specimen was included independently in the analysis; (4) 
if both positive and negative viral results were reported 
from specimens obtained within a 14  day period, only 
the positive result(s) were included; and (5) if differ-
ent viruses were detected on repeat specimens within a 
14 day period, all viral agents were considered to be from 
a single sample in the analysis, as were specimens with 
multiple viruses detected in a single swab.
Pediatricians and primary care physicians were 
informed by the local health jurisdiction during the 
state-wide pertussis outbreak period regarding clini-
cal criteria meeting 2010 case definition for pertussis or 
whooping cough illness published by Centers for Disease 
Control and Prevention (CDC) [11]. The assessment of 
physician suspicion of pertussis as a potential diagnosis 
was based on presence of pertussis laboratory orders for 
LD-PCR alone by the responsible physician. The assess-
ment of physician suspicion of potentially either a res-
piratory viral or pertussis infection was based on the 
presence of physician orders for both pertussis by LD-
PCR and respiratory viruses by RM-PCR. We there-
fore planned to evaluate three groups (or cohorts) in 
our analysis: (1) children suspected for pertussis alone 
(with only LD-PCR for pertussis ordered); (2) children in 
whom pertussis was not suspected (with only RM-PCR 
for respiratory viruses ordered); and (3) children sus-
pected for viral illness and/or pertussis (with both LD-
PCR and RM-PCR ordered).
Specimens
Deep posterior nasopharyngeal (NP) specimens collected 
on thin-aluminum wire shafts with small Dacron/Rayon 
swab tips (Hardy Diagnostics, Santa Maria, CA), kept at 
4  °C without transport medium, were required for daily 
batch testing by LD-PCR. Nylon flocked mid-turbinate 
(midNT) swabs on a flexible plastic shaft rotated 360° and 
inoculated in 3-ml Universal Transport Medium (UTM, 
Copan Diagnostics, Brescia, Italy) were sent promptly for 
RM-PCR. Two lengths of nylon flocked swabs were used, 
both with circular collars to ensure standard sampling 
with indicator for depth: one with a shaft length of 2.5 cm 
(code 56750CS01) for children ≤2 years or a 5.5 cm long 
shaft (code 56380CS01) for children >2 years [12]. Sam-
ples were typically collected by trained nurses and trans-
ported to the laboratory within 1 h.
LD‑PCR for pertussis pathogens
NP swabs were refrigerated if >2 h delay in transport was 
anticipated. The NP specimen was eluted by vortexing 
for 20  s in 1  ml saline and concentrated by centrifuga-
tion [8]. The LD-PCR was designed to detect and dif-
ferentiate B. pertussis, B. parapertussis, and B. holmesii 
based on three species-discriminative DNA targets and 
melt peak characteristics [8]. In addition, LD-PCR could 
accommodate up to 10 specimens per 96-well plate with 
2.5  h batches feeding into 3–4 thermocyclers during 
specimen surges [13]. The limit of detection for LD-PCR 
was determined to show 90 % reproducibility at a mini-
mum of 15 copies per PCR reaction. Consensus crite-
ria for interpreting results used 3 targets, where either 
2–3 positive targets with specific melt curve (IS481, ptx 
promoter region, and/or recA) or a single reproducible 
positive target were accepted as positives, with a con-
tingency that if IS481 was the only target positive, test 
to rule out B. holmesii is carried out [8]. Testing was 
batched; results were typically available within 4–15  h. 
Bacterial culture for pertussis was performed on all 
PCR-positive specimens by inoculating the same swab 
(post PCR elution) on Regan-Lowe agar. A sheep blood 
agar was added if specimen was positive for B. paraper-
tussis or B. holmesii. Phenotypic colonies from Regan-
Lowe or non-selective blood agar were further speciated 
and confirmed by LD-PCR.
RM‑PCR for respiratory viruses and pertussis
MidNT swabs in UTM were submitted to the laboratory 
at room temperature within 1 h [7]. After 20 s of vortex, 
an aliquot of the solution was added to the RM-PCR card 
according to manufacturer’s specifications (BioFire). The 
RM-PCR utilizes a two-step nested multiplex PCR pro-
cess, including primary multiplex PCR followed by an 
array of organism-specific second-stage PCR reactions 
[14]. The RM-PCR for pertussis targets only the toxin 
promoter region; cross reactivity with B. parapertus-
sis is not observed at concentrations less than 106 CFU/
ml [15]. Although the limit of detection was listed in 
the FilmArray product description for B. pertussis at 
4000 CFU/ml, we have further verified that the sensitiv-
ity of the test can approach 31 CFU/ml using serial dilu-
tions running in duplicate. The specific RM-PCR panel 
at the time was approved to detect 8 viral pathogens and 
their subtypes, including influenza A (Flu A), influenza 
B (Flu B), RSV, parainfluenza viruses(PIV) 1–4, human 
metapneumovirus (HMPV), coronavirus (CoV) HKU1 
and NL63, adenovirus (AdV), and rhinovirus/enterovi-
rus (RhV). This assay detected but did not reveal results 
from three bacterial pathogens (B. pertussis, C. pneumo-
niae, and M. pneumoniae) until FDA approval in Octo-
ber, 2012.
Page 4 of 7Qin et al. Ann Clin Microbiol Antimicrob  (2016) 15:28 
Statistical analysis
Proportions were compared using Chi square, McNe-
mar’s exact Chi square, two-sample test of proportions, 
and one-way ANOVA as appropriate. Statistical analyses 




Altogether, 1075 (94.1  %) of 1142 NP specimens tested 
by LD-PCR met inclusion criteria for analysis while 
3566 (64.4 %) of 5523 midNT specimens tested by RM-
PCR were included (Table  1; Fig.  1). Patients with NP 
specimens tested by LD-PCR alone were designated 
as “Cohort 1” (n  =  584; Table  1; Fig.  1). Patients with 
midNT specimens tested by RM-PCR alone for res-
piratory viral pathogens was designated as “Cohort 2” 
(n = 3071; Table 1; Fig. 1). “Cohort 3” was defined as the 
group of patients on whom both LD-PCR and RM-PCR 
were ordered within 72 h of each other and are otherwise 
described as “dual-tested” specimens (n =  490; Table  1; 
Fig. 1).
Results of pertussis diagnostic assays
The performances of LD-PCR and RM-PCR for detection 
of pertussis pathogens were compared in the dual-tested 
group, Cohort 3 (n = 490). A total of 27 (5.5 %) positive 
specimens were detected in this cohort, including both B. 
pertussis (n = 25) and B. parapertussis (n = 2) (Table 1; 
Fig. 1). If the combined detection of pertussis pathogens 
(total n =  27, including two B. parapertussis) by either 
RM-PCR or LD-PCR was used as the reference stand-
ard, LD-PCR detected 22 of the 27 (81  %) while RM-
PCR detected 24 of the 27 (89  %). If excluding the two 
cases of B. parapertussis (a species not included in the 
RM-PCR panel), LD-PCR detected 20 of the 25 (80  %) 
B. pertussis while RM-PCR detected 24 of the 25 (96 %, 
p  =  0.2 for difference in proportions by McNemar’s 
exact Chi square). Two of 5 cases of B. pertussis missed 
by LD-PCR were positive for a single target but were not 
Table 1 Comparison of  viral and  Bordetella pathogen detection rate among  cohorts of  patients with  different tests 
ordered by clinicians
a n: includes B. parapertussis
Cohort 1: pertussis PCR 
alone
N = 584 (% positive)
Cohort 2: viral PCR alone
N = 3071 (% positive)
Cohort 3: dual tested
N = 490 (% positive)
p value
Median age 3 years 2 years 0.54 years <0.001
Age range 6 days–21 years 3 days–21 years 2 days–20 years NA
Patient age <24 months 240 (41 %) 1268 (41 %) 369 (75 %) <0.001
Bordetella pathogen detec-
tion by LD-PCR (%)
n = 21 (3.6 %), including 3 B. 
parapertussisa
NA n = 22 (4.5 %), including 2 B. 
parapertussisa
0.5
B. pertussis detection by RM-
PCR (%)
NA n = 4 (0.1 %) n = 24 (4.9 %) <0.001
Combined detection by both 
RM-PCR and LD-PCR: n (%)
NA NA n = 27 (5.5 %), including 2 B. 
parapertussisa
NA
Organism isolation by culture: 
n (% of culture positive over 
detection by LD-PCR)
n = 14 (14/21 or 66.7 %), 
including 2 B. parapertussisa
NA n = 10 (10/22 or 45.5 %), includ-
ing one B. parapertussisa
0.16
Rate of viral positive detec-
tion: n (%)
NA 1988 (64.6 %) 367 (74.8 %) <0.001
Rate of viral positive in 
patients age < 24 months: 
n/n (%)
NA 840/1268 (66.2 %) 290/369 (78.6 %) <0.001
Flu A NA 164 (5.3) 17 (3.5) <0.001 (combined Flu 
A and B rates)Flu B NA 360 (11.7) 30 (6.1)
PIV 1-4 NA 83 (2.7) 33 (6.7) <0.001
RSV NA 433 (14.1) 124 (25.3) <0.001
HMPV NA 186 (6.0) 35 (7.1) 0.4
AdV NA 88 (2.9) 17 (3.5) 0.5
RhV NA 741 (24.1) 143 (29.2) 0.02
CoV NA 111 (3.6) 24 (4.9) 0.17
2–3 Viruses NA 170 (5.5) 54 (11.0) <0.001
Page 5 of 7Qin et al. Ann Clin Microbiol Antimicrob  (2016) 15:28 
reproducible; the one case missed by RM-PCR was posi-
tive for a single target and reproducible by LD-PCR.
Six of the 490 specimens in Cohort 3 had discord-
ant results, with one specimen positive only by LD-PCR 
only and 5 samples positive by RM-PCR only (Table 1). 
The median age of these 6 subjects was 1.9 years (range 
6 weeks to 10 years), with respiratory symptoms present 
for a median of 5.5 days prior to testing (range 2–9 days). 
All six subjects had cough at their clinical assessment, 
and four of these reported coughing paroxysms. Only 
one child had a known exposure to pertussis, occurring 
7 weeks earlier, and had received post-exposure prophy-
laxis with a macrolide antibiotic. Three of these six cases 
(all positive by RM-PCR) had pertussis diagnosed at 
another facility (method unknown) within 3 days prior to 
evaluation at our institution.
Recognition of pertussis by clinicians
We evaluated the ability of clinicians to recognize per-
tussis by using the tests ordered as a proxy for phy-
sician recognition of pertussis (Table  1). Patients in 
Cohort 1 (n  =  584) included those who were strongly 
suspected to have pertussis, as only LD-PCR was 
requested. In this cohort, patient age ranged from 6 days 
to 21  years [median, 3  years, inter-quartile range (IQR) 
0.83–7  years], and the rate of pertussis detection was 
3.6  %, representing 18 cases of B. pertussis and three 
cases of B. parapertussis (Table 1).
Patients in Cohort 2 (n = 3071) had specimens submit-
ted only for respiratory viral pathogen detection, indi-
cating that pertussis was not suspected. In this cohort, 
patient age ranged from 3  days to 21  years (median, 
2  years, IQR 1.08–7  years). B. pertussis was detected in 
only 4 specimens (0.1 %) after obtaining un-blinded RM-
PCR results post hoc, a rate significantly different than 
that in Cohort 1 (p < 0.001 for comparison, Table 1).
Specimens collected in Cohort 3 (n = 490) were from 
individuals with age range 2  days–20  years (median 
0.54  years, IQR 0.16–1.92  years) whose healthcare pro-
viders requested both LD-PCR for pertussis and RM-
PCR for respiratory viruses. Patients in Cohort 3 tended 
to be younger than patients in the other two cohorts: 
the proportion of patients <24  months of age was 41  % 
in Cohort 1, 41  % in Cohort 2, and 75  % in Cohort 3 
(p  <  0.001 by Chi square). The detection of pertus-
sis pathogens in Cohort 3 was the highest of all three 
cohorts (5.5 %), with 2 B. parapertussis (Table 1).
Clinically unsuspected pertussis detection
Four children from Cohort 2 (respiratory viral testing 
ordered but not pertussis-specific testing) had pertussis 
detected by RM-PCR (based on data recovered by the 
manufacture post hoc), including one case previously 
diagnosed at another institution. The median age of these 
4 subjects was 6.6 years (range 6 weeks to 14 years), and 
the median duration of respiratory symptoms prior to 
testing was 5  days (range 2–14  days). All four subjects 
had cough as a clinical finding but coughing paroxysms 
were not reported, and there was no indication of receipt 
of macrolides in the medical record.
Respiratory viral infections
Pertussis and respiratory viral pathogens were present 
in respiratory specimens in all age groups and all study 
months (Table 1, Fig. 1). Although the rate of viral infec-
tions in Cohort 1 is not known, the overall viral detection 
rates in Cohorts 2 and 3 were high, at 64.6 and 74.8  % 
respectively overall (p  <  0.001, Table  1), and 66.2 and 
78.6 % respectively among those <24 months (p < 0.001, 
Table 1). Detection rates of specific viruses also differed 
between Cohorts 2 and 3. In particular, the incidence of 
influenza (Flu A and Flu B) was higher in Cohort 2 (17.0 
vs. 9.6 %, p < 0.001). By contrast, Cohort 3 had a higher 
incidence of RSV (25.3 vs. 14.1 %), PIV (6.7 vs. 2.7 %), or 
multiple viruses (11 vs. 5.5 %), all p < 0.001 (Table 1).
Viral and pertussis co‑infections
Viral co-infections were common in specimens with 
pertussis. Three of four specimens positive for B. per-
tussis in Cohort 2 also had viruses detected—two cases 
with HMPV and one with Flu B. Sixteen of the 27 (59 %) 
specimens positive for pertussis pathogens in Cohort 
3 had simultaneous detection of viral agents: RhV in 8, 
CoV in 6, and one each for PIV, HMPV and RSV. Two of 
16 specimens contained more than one viral agent—one 
with RhV and PIV, the other with CoV and HMPV.
Culture confirmation of pertussis detected by LD‑PCR
Bacterial culture was performed in all 43 specimens posi-
tive by LD-PCR (21 from Cohort 1 and 22 from Cohort 
3). Pertussis pathogens were isolated from 55.8 % of these 
43 specimens (n = 24; B. pertussis from 21 and B. para-
pertussis from 3 specimens) after 2–15  days of incuba-
tion—demonstrating the slow turn-around time and poor 
diagnostic utility of pertussis culture (Table  1). Rates 
of isolation of viable organisms were similar (p =  0.16) 
between Cohort 1 (14/21, 66.6 %) and Cohort 3 (10/22, 
45.5  %). None of the 6 specimens with discrepant find-
ings between LD-PCR and RM-PCR had positive culture 
results.
Discussion
We assessed the ability of an RM-PCR platform and an 
LD-PCR test to detect pertussis pathogens in the context 
of a state-wide pertussis epidemic. Based on the retro-
spective analysis, the two PCR assays achieved similar 
Page 6 of 7Qin et al. Ann Clin Microbiol Antimicrob  (2016) 15:28 
sensitivity despite their differences in sampling, collec-
tion media, and amplification technology. We also found 
that clinicians were relatively effective at identifying chil-
dren at higher risk for pertussis.
In this study, we demonstrated that both midNT speci-
mens collected with nylon flocked swabs and NP speci-
mens collected with Dacron/Rayon swabs were effective 
for B. pertussis detection. These results are similar to 
findings reported by Esposito et al. [12] and Walsh et al. 
[16]. Anecdotally, in our center the use of midNT swabs 
is preferred by health care professionals as the depth of 
sampling can be standardized with age appropriate visual 
guides. This approach may in fact promote standardized 
collection of high quality specimens.
Over the past decade remarkable progress has been 
made in the development of RM-PCR methods for the 
concomitant rapid diagnosis of viral and bacterial res-
piratory infections [7]. Our results suggest similar per-
formance between RM-PCR and LD-PCR methods in 
identifying pertussis pathogens. Although we were unable 
to culture pertussis from the 6 samples with discordant 
results, these cases are likely to be true positives based on 
evidence of exposure to pertussis, detection of pertussis 
by other laboratories, and/or the presence of coughing 
paroxysms. It is possible that the discordant specimens 
had low copy number of B. pertussis DNA and/or sam-
pling variation. The 5 cases missed by LD-PCR could 
potentially also be related to PCR inhibition with alu-
minum-shaft swabs [17]. Limitations associated with the 
design of RM-PCR include the capacity to test only one 
specimen at a time and to detect only B. pertussis. Conse-
quently, the emergence of B. parapertussis and B. holmesii 
may be overlooked [13, 18]. In addition, the use of antibi-
otic-containing media for specimen collection precludes 
culture for viable organisms, necessitating both molecular 
and epidemiological investigations [3, 19].
The accuracy of clinical diagnosis of viral versus pertus-
sis infection in children has not been well documented 
[20]. Clinicians’ abilities to identify patients at risk for 
pertussis appeared to be relatively effective in our study; 
pertussis pathogens were detected over 50 times more 
frequently in dual-tested Cohort 3 (5.5  %) compared to 
those ordered only for viral testing (Cohort 2, 0.1  %). 
Influenza appeared to be recognized by clinicians as well; 
nearly twice as many laboratory-confirmed Flu A/B cases 
occurred in the viral-only tested Cohort 2 compared 
to the dual tested Cohort 3 (17 vs. 9.6  %, respectively; 
p < 0.001). Our retrospective analysis supports the use of 
RM-PCR in children <24 months as the findings of both 
respiratory viruses (including multi-viral co-infections) 
and pertussis are significantly higher in this age group 
(Table 1).
The implementation of an innovative RM-PCR assay 
including respiratory viral and bacterial pathogens in a 
hospital-based laboratory is not without its own chal-
lenges. Although clinical assessment can be effective, 
ordering of a single test that produces multiple results 
can be problematic. Existing laboratory billing models 
and its governance have not yet caught up with these 
multiplex PCR platforms, and the assignment and com-
munication of “unrequested” agents generated by such 
broad test panels can potentially cause operational chal-
lenges and reimbursement difficulties for the laboratory 
and the institution [13, 21].
Our study was limited by the retrospective design and 
the lack of complete parallel data for both pertussis and 
respiratory viruses at every patient visit. We also note 
that our study occurred during a period of high aware-
ness of pertussis disease. However, the unsolicited test 
selection and specimen collection by multiple clinicians, 
combined with the ability to obtain pertussis data from 
viral test specimens retrospectively, permitted the anal-
ysis of physician clinical decision making without study 
bias.
Our experience during a pertussis epidemic demon-
strated the diagnostic acumen of clinicians, the ability to 
use mid-nasal flocked swabs to detect pertussis without 
compromise in sensitivity when compared to NP speci-
mens, and the correlation of results from an integrated 
bacterial-viral RM-PCR assay with a more labor-inten-
sive, well-established, multi-target LD-PCR assay during 
a specimen surge. The RM-PCR platform has the ability 
to identify relevant respiratory pathogens quickly, with 
implications for both optimal treatment and infection 
prevention management in younger children.
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